An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension

AIMS/HYPOTHESIS: Praliciguat (IW-1973), a soluble guanylate cyclase stimulator, amplifies nitric oxide signalling. This exploratory trial investigated the safety, tolerability, pharmacokinetic profile and pharmacodynamic effects of praliciguat in individuals with type 2 diabetes and hypertension. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanrahan, John P., Seferovic, Jelena P., Wakefield, James D., Wilson, Phebe J., Chickering, Jennifer G., Jung, Joon, Carlson, Kenneth E., Zimmer, Daniel P., Frelinger, Andrew L., Michelson, Alan D., Morrow, Linda, Hall, Michael, Currie, Mark G., Milne, G. Todd, Profy, Albert T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054374/
https://www.ncbi.nlm.nih.gov/pubmed/31858186
http://dx.doi.org/10.1007/s00125-019-05062-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054374/
https://www.ncbi.nlm.nih.gov/pubmed/31858186
http://dx.doi.org/10.1007/s00125-019-05062-x

Ejemplares similares